Mark Agulnik

15PUBLICATIONS
89CO-AUTHORS
Molecular targetsClinical pharmacology and therapeuticsPredictive and prognostic markersPacific Peoples theory of change models for healthCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

|Mar 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.

Mrinal Gounder, Patrick Schöffski, Robin L Jones

|Jan 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.

Breelyn A Wilky, Gary K Schwartz, Michael S Gordon

|Dec 11, 2024
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.

J Andrew Livingston, Jean-Yves Blay, Jonathan Trent

|Apr 27, 2024
Prices and Trends in FDA-Approved Medications for Sarcomas.

Caleb Hwang, Mark Agulnik, Brian Schulte

|Oct 27, 2023
Bioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma.

Adam Rock, An Uche, Janet Yoon

Pageof 3

Frequent Collaborators

4 joint publications

Brian Van Tine

3 joint publications

Angela C Hirbe

2 joint publications

Robin L Jones

2 joint publications

Jonathan Trent